Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.

PURPOSE To establish the rate of resolution of prostatic edema following transperineal interstitial permanent prostate brachytherapy, and to determine the results and impact of timing of the postimplant assessment on the dose-volume relationship. METHODS AND MATERIALS A series of 19 consecutive patients with early-stage adenocarcinoma of the prostate receiving transperineal interstitial permanent prostate brachytherapy, were enrolled in this study. Twelve received 125I and seven received 103Pd. Postoperative assessment included a computed tomographic (CT) scan on postoperative days 1, 8, 30, 90, and 180. On each occasion, CT scans were performed on a GE helical unit at 3-mm abutting slices, 15-cm field of view. Prostate volumes were outlined on CT scans by a single clinician. Following digitization of the volumes and radioactive sources, volumes and dose-volume histograms were calculated. The prostate volume encompassed by the 80% and 100% reference isodose volumes was calculated. RESULTS Preimplant transrectal ultrasound determined volumes varied from 17.5 to 38.6 cc (median 27.9 cc). Prostate volumes previously defined on 40 randomly selected postimplant CT scans were compared in a blinded fashion to a second CT-derived volume and ranged from -32% to +24%. The Pearson correlation coefficient for prostate CT volume reproducibility was 0.77 (p < 0.03). CT scan-determined volume performed on postoperative day 1 was an average of 41.4% greater than the volume determined by preimplant ultrasound. Significant decreases in average volume were seen during the first month postoperatively. Average volume decreased 14% from day 1 to day 8, 10% from day 8 to day 30, 3% from day 30 to day 90, and 2% thereafter. Coverage of the prostate volume by the 80% isodose volume increased from 85.6% on postoperative day 1 to 92.2% on postoperative day 180. The corresponding increase in the 100% reference dose coverage of the prostate volume ranged from 73.1% to 83.3% between postoperative days 1, and 180, respectively. CONCLUSIONS Most of the prostatic edema induced by brachytherapy appears to resolve by postoperative day 30. Scans performed on postimplant day 30 appear to adequately describe the time-averaged dose coverage of the prostate. This suggests that waiting approximately 1 month to perform postimplant analysis gives the most accurate prostatic volume and, consequently, dosimetric description of the implant.

[1]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[2]  A B Wolbarst,et al.  Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. , 1987, International journal of radiation oncology, biology, physics.

[3]  2210 A comparison of MRI and CT based post implant dosimetric assessment of transperineal interstitial permanent prostate brachytherapy , 1997 .

[4]  J. Blasko,et al.  A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems. , 1997, International journal of radiation oncology, biology, physics.

[5]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[6]  J. Blasko,et al.  Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[7]  H. Hricak,et al.  Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[8]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[9]  J. Oesterling,et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.

[10]  1010 Source localization using magnetic resonance imaging following permanent transperineal interstitial prostate brachytherapy , 1997 .

[11]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[13]  A. Brahme,et al.  Optimization of radiation therapy , 1994 .